Opinion|Videos|October 14, 2024
Genetic Testing – Somatic
Author(s)Neal D. Shore, MD, Petros Grivas MD, PhD
Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.
Advertisement
Episodes in this series
If a patient has a negative germline test, do they need to get somatic?
Advertisement
Related to this article
In a Roswell Park study, changes focused on standardization of care and donor selection, contributing to a 1-year overall survival rate of 92.6%.
Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.
Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Long-term follow-up from the REVIVE and THRIVE studies showed a low thromboembolic event rate with rusfertide in phlebotomy-dependent polycythemia vera.
The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera
5